Cost Containment Pressure vs. Access to Innovative but Expensive Therapies

Business Context

Health system and payer leadership face continuous pressure to contain costs, since healthcare spending growth that outpaces revenue growth threatens both organizational sustainability and, at a system level, the affordability of care for the broader population. At the same time, genuinely innovative therapies, including certain novel pharmaceuticals and advanced procedures, can offer substantial clinical benefit for specific patients, and restricting access purely on cost grounds can mean withholding meaningfully beneficial care, creating a direct tension between financial stewardship and clinical benefit for individual patients.

Healthcare TRIZ Resolution

Rather than applying uniform cost restriction across all innovative therapies regardless of demonstrated value, or approving access without cost-conscious evaluation, the resolution implements structured value-based access criteria, developed by clinical and financial leadership together, that evaluate each innovative therapy against defined clinical evidence and outcome thresholds specific to the patient populations most likely to benefit, approving access preferentially for patients meeting these evidence-based criteria, while directing more conservative decision-making toward populations or indications where evidence of meaningful benefit is weaker, replacing a single blanket cost decision with a differentiated, evidence-anchored one.

Applicable TRIZ Principles

Principle 1 – Segmentation Differentiate access decisions by patient population and evidence strength rather than a single uniform approval or restriction applied to an entire therapy.

Principle 3 – Local Quality Direct access specifically toward the patient populations with the strongest evidence of meaningful clinical benefit.

Principle 40 – Composite Materials Combine clinical and financial expertise in a joint evaluation process rather than treating cost containment and clinical benefit as separately owned decisions.

Expected Outcome

Preserved access for high-benefit patients

More sustainable overall cost trajectory

Evidence-anchored access decisions

Reduced blanket restriction

Decision Indicators

Early indicators that this contradiction is limiting organizational performance include:

Access decisions for innovative therapies made through blanket approval or restriction without differentiation by patient population or evidence strength

No joint clinical-financial evaluation process for high-cost innovative therapy access decisions

Clinicians reporting they are unable to access clearly evidence-supported therapies for patients who meet strong clinical criteria

Spending on innovative therapies concentrated in populations with weaker evidence of meaningful benefit

No periodic reassessment of access criteria as new evidence about a given therapy’s benefit profile emerges

Monitoring these indicators helps clinical and financial leadership evaluate whether cost containment decisions are appropriately calibrated to genuine clinical value.